NeuroPace, Inc. (NPCE) Stock

NeuroPace, Inc. (NPCE) is a Healthcare stock trading at $15.60 (as of 2026-06-18), with a market capitalization of $563.91M and a trailing P/E of -25.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

NeuroPace, Inc. is a U.S. medical device company that develops and sells the RNS system, a brain-responsive neuromodulation platform for patients with medically refractory focal epilepsy. The system delivers real-time stimulation and records continuous brain activity to support clinician monitoring, with products sold to hospitals for implant and replacement procedures.

Valuation — source: SEC EDGAR (first-party)
Price	$15.60
Market Cap	$563.91M
P/E Ratio	-25.4
EV / EBITDA	-36.8
Price / Book	39.01
Price / Sales	5.67
DCF Value (model)	$-6.83
DCF Upside vs Price	-143.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$99.99M
Net Margin	-21.5%
Return on Equity	-149.2%
Debt / Equity	4.08
Current Ratio	5.38
Revenue Growth (YoY)	25.1%
EPS Growth (YoY)	-29.0%
FCF Growth (YoY)	-37.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	-2.38 (distress)
Piotroski F-Score	5/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-25.4
Sector P/E (Healthcare)	21.0
Industry P/E (Medical Equipment)	31.7
vs Sector	-221.4%
vs Industry	-180.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Polar Capital Holdings Plc ($43.37M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Joel D. Becker
Employees	184
Country	US
IPO Date	2021-04-22

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.